Germany: Grünenthal targets testosterone deficiency with acquisition of Nebido

Aachen-headquartered Grünenthal, a global science-based, privately-owned pharmaceutical company, and a specialist in pain management, is acquiring Nebido, the well-known brand for the treatment of male hypogonadism and its associated brands, from Bayer AG for up to €500m (US$507m). Nebido is the leading brand in the treatment of male hypogonadism and the only long-acting injectable treatment for…

You must be a HMI Subscriber to view this content.

Subscribe Now »